Treatment of macular edema associated with retinal vein occlusion using sustained-release dexamethasone implants in a clinical setting

European Journal of Ophthalmology

Volumn 23, Issue 4, 2013, Pages 558-563

  Merkoudis, Nikolaos ^a   Granstam, Elisabet ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dexamethasone implant; Intraocular pressure; Ischemia; Ozurdex; Steroids; Vascular endothelial growth factor

Indexed keywords

DEXAMETHASONE; EYE DROPS;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; PATIENT SAFETY; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETINAL IMPLANT; RETREATMENT; SLOW RELEASE FORMULATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; ANTI-INFLAMMATORY AGENTS; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; VISUAL ACUITY;

EID: 84878438874     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000261     Document Type: Article

References (24)

1. Rogers S, McIntosh RL, Cheung N, et al. International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-9.
2. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recur-rence and demographic characteristics. Am J Ophthalmol 1994;117:429-41.
3. Yau JW, Lee P, Wong TY, Best J, Jenkins A. Retinal vein oc-clusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008;38:904-10.
4. Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol 2009;147:11-21.
5. Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009;4:e8158.
6. Noma H, Funatsu H, Harino S, Mimura T, Eguchi S, Hori S. Vitreous inflammatory factors in macular edema with central retinal vein occlusion. Jpn J Ophthalmol 2011;55:248-55.
7. Coscas G, Coscas F, Zucchiatti I, Glacet-Bernard A, Sou-brane G, Souïed E. SD-OCT pattern of retinal venous occlu-sion with cystoid macular oedema treated with Ozurdex®. Eur J Ophthalmol 2011;21:631-6.
8. McAllister IL, Vijayasekaran S, Chen SD, Yu DY. Effect of tri-amcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 2009;147:838-46.
9. Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008;31:1541-6.
10. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous con-centrations of various cytokines after intravitreal triamcino-lone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011;152:686-94.
11. Haller JA, Bandello F, Belfort R Jr, et al. OZURDEX GE-NEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macu-lar edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46.
12. Haller JA, Bandello F, Belfort R Jr, et al. Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-60.
13. Campochiaro PA, Heier JS, Feiner L, et al. BRAVO Inves-tigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12.
14. Brown DM, Campochiaro PA, Singh RP, et al. CRUISE Inves-tigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-33.
15. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology 1991;98(Suppl):807-22.
16. Michaelides M, Fraser-Bell S, Hamilton R, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina 2010;30:781-6.
17. Parodi MB, Iacono P, Cascavilla M, et al. Compassionate use of dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion in a clinical setting. Acta Ophthalmol 2012;90:e322-3.
18. Parodi MB, Iacono P, De Benedetto U, Cascavilla M, Bandello F. Rebound effect after intravitreal dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion. J Ocul Pharmacol Ther 2012;28:566-8.
19. Mayer WJ, Remy M, Wolf A, et al. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema. Ophthalmologica 2012;228:110-6.
20. Ip MS, Scott IU, VanVeldhuisen PC, et al. The SCORE study research group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-14.
21. Scott IU, Ip MS, VanVeldhuisen PC, et al. The SCORE study research group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-28.
22. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;141:876-83.
23. Yeh WS, Haller JA, Lanzetta P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 2012;119:1190-8.
24. Coscas G, Loewenstein A, Augustin A, et al. Management of retinal vein occlusion-consensus document. Ophthalmologica 2011;226:4-28.